By Fineline Cube 
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.
Clinical Trial Results
The JSKN003-101 and JSKN003-102 studies, conducted in Australia and China, respectively, demonstrated that JSKN003 exhibited high objective response rates (ORR) and disease control rates (DCR) across different indications and HER2 expression levels. The drug showed a favorable safety profile, with most adverse events being mild to moderate. The incidence of severe adverse events was low, and no treatment-related deaths were reported.
JSKN003 Mechanism and Development
JSKN003 is a HER2 bispecific epitope antibody-drug conjugate (ADC) designed to enhance binding affinity by targeting two distinct epitopes on HER2. This mechanism improves drug internalization and bystander killing effects, strengthening antitumor activity against HER2-expressing solid tumors while maintaining good serum stability. JSKN003 is currently the subject of multiple Phase III clinical trials in China, covering indications such as HER2-positive breast cancer, HER2-low breast cancer, and platinum-resistant recurrent epithelial ovarian cancer.-Fineline Info & Tech